Rituximab, MMF may be effective off-label options for NMOSD: Study
Rituximab and mycophenolate mofetil may be the most effective off-label options for neuromyelitis optica spectrum disorder (NMOSD) patients who are unable to access approved therapies, often due to high costs or limited availability, according to a study in China. The study compared the safety and efficacy of four immunosuppressive therapies…